People

Rich Aldrich

Rich AldrichMr. Aldrich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Vertex Pharmaceuticals (NASDAQ: VRTX), Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by Glaxo in 2008), Concert Pharmaceuticals (NASDAQ: CNCE), where he serves as Chairman of the Board, and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), OvaScience (NASDAQ: OVAS), Verastem (NASDAQ: VSTM) and Axial Biotherapeutics. Mr. Aldrich also serves as Chairman of the Board of Directors at Longwood portfolio company KalVista Pharmaceuticals and is a Director of Longwood portfolio companies Mitobridge, Inc., Colorescience, Inc. and Renovia, Inc. Prior to co-founding Longwood, Mr. Aldrich was General Partner of RA Capital, a biotechnology investment fund he co-founded in 2001. Mr. Aldrich was a founding employee of Vertex where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.

Michelle Dipp, M.D., Ph.D.

Michelle Dipp, M.D., Ph.D.Dr. Dipp is a co-founder and Partner of Longwood Fund. Dr. Dipp has co-founded Longwood portfolio companies Axial Biotherapeutics, where she serves as Chairman of the Board, OvaScience (NASDAQ: OVAS) where she previously served as co-founding CEO and Chairman of the Board, Alnara Pharmaceuticals (acquired by Eli Lilly), Verastem (NASDAQ: VSTM) and FlexPharma (NASDAQ: FLKS). Dr. Dipp also serves on the Boards of Longwood portfolio companies Colorescience and Bicycle Therapeutics (Observer). Previously, Dr. Dipp was the Senior Vice President and Head of GlaxoSmithKline’s (NYSE: GSK) Centre of Excellence for External Drug Discovery (CEEDD). Prior to leading GSK's CEEDD, Dr. Dipp was the Vice President of Corporate Development at Sirtris (NASDAQ: SIRT acquired by GSK). Before joining Sirtris as a co-founder, she worked in healthcare private equity at The Wellcome Trust in London. Dr. Dipp holds a BM, BCh (MD equivalent) from University of Oxford Medical School and a DPhil (PhD equivalent) in Physiology from the University of Oxford. Dr. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital, Oxford. Dr. Dipp serves on the Biotechnology Industry Organization's (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, as well as on non-profits including the Life Science Cares Board, the Beth Israel Deaconess Medical Center Board of Directors, the Beth Israel Institute for RNA Medicine Advisory Board, and the Boston Symphony Orchestra Board of Overseers. In 2015, Dr. Dipp was elected to join the World Economic Forum's Young Global Leaders and was named to Fortune magazine's 40 Under 40 list. Dr. Dipp is a women's health contributor for Arianna Huffington's Thrive Global.

Christoph Westphal, M.D., Ph.D.

Christoph Westphal, M.D., Ph.D. Dr. Westphal is a co-founder and Partner of Longwood Fund. Dr. Westphal was co-founder, CEO, and lead investor of six biotech companies that have completed IPOs: Momenta (NASDAQ: MNTA), Alnylam (NASDAQ: ALNY), Acceleron (NASDAQ: XLRN), Sirtris (NASDAQ: SIRT; acquired by GSK), Verastem (NASDAQ: VSTM), and Flex (NASDAQ: FLKS). He co-founded two additional companies that completed IPOs: Concert Pharmaceuticals (NASDAQ: CNCE) and Ovascience (NASDAQ: OVAS). He also co-founded Alnara (acquired by Lilly) and Axial (private). Companies co-founded by Dr. Westphal have developed and received FDA approval for important drugs, including the largest-selling heparin in the US, and a therapy for MS; and several experimental medicines: for Cystic Fibrosis (phase 3), for currently incurable cancers (phase 3), for serious inflammatory disorders (phase 2) and for serious neurological illnesses such as ALS, MS, and Charcot Marie Tooth (phase 2). In addition, these companies have created substantial shareholder value and aggregate, sustained market capitalizations of over $12 billion. Companies co-founded by Dr. Westphal have created roughly 1,000 good jobs in the Boston area.

Dr. Westphal serves on the BIO Emerging Companies Section Governing Board, the Board of Fellows of Harvard Medical School, the Board of Overseers of the Boston Symphony Orchestra, and is a member of the Boston Commercial Club. He earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University and graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in leading journals such as Cell, Nature and Nature Genetics. Dr. Westphal has been featured in the media, including on '60 Minutes', CNN, an ABC News Special hosted by Barbara Walters and as the subject of a Fortune cover article.

David H. Donabedian, Ph.D.

David H. Donabedian, Ph.D.Dr. Donabedian is a Venture Partner and current Chief Executive Officer and co-founder of Longwood portfolio Company Axial Biotherapeutics. Dr. Donabedian also serves on the Board of Longwood portfolio company Millendo therapeutics. Dr. Donabedian is an accomplished business development and strategy executive with extensive leadership experience and a track record of building companies. Prior to joining Longwood, Dr. Donabedian has held various leadership roles at biopharmaceutical companies including AbbVie (NASDAQ: ABBV) and GSK (NYSE: GSK). At AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations where he led a global team that completed significant transactions across multiple therapeutic areas and stages of development. Prior to AbbVie, Dr. Donabedian served as Vice President Global New Deal Strategy and Development at GlaxoSmithKline, and Senior Manager at Accenture's Strategic Services Consulting Group.

Dr. Donabedian holds a BA in Chemistry from St. Anselm College, a Ph.D. in Polymer Chemistry from the University of Massachusetts Lowell, and an MBA from the University of North Carolina. He currently serves on the Board of Alcyone Life Sciences, a privately held CNS company which he co-founded.

Brian Malone, B.Sc., F.C.A.

Brian Malone, B.Sc., F.C.A. Mr. Malone is the Chief Financial Officer of Longwood where he has responsibility for all financial and operational aspects of the Funds and the management company. He has over 30 years' experience in financial services worldwide, having worked in Europe and the UK with the last 15 years spent in the Boston, MA. He has an honors degree in science from University College Dublin and is a Fellow of the Irish Institute of Chartered Accountants. Additionally he has postgraduate qualifications in information technology from Dublin City University and in International Financial Reporting Standards.

Brian Malone started his career in Dublin, Ireland with Ernst & Young before moving to Guernsey in the Channel Islands where he worked for KPMG, Barings and Old Mutual. He moved to London to take a role as Chief Financial Officer of Old Mutual's Investment Management business. He was involved with the listing of Old Mutual on the London Stock Exchange (ticker OML).

Margaret Dipp

Margaret Dipp Ms. Dipp leads Investor Relations at Longwood Fund. Prior to joining Longwood, Ms. Dipp was a Senior Associate heading up Investor Relations at Brazos Private Equity Partners. Prior to Brazos, Margaret was a Private Equity Analyst in the Investor Relations and Fund Placement division of The Blackstone Group. Ms. Dipp received a Bachelor of Arts degree with high honors from Southern Methodist University and a Masters in International Relations from Oxford University.

 

Strategic Advisory Board

James Foster
Chairman of the Board, President and Chief Executive Officer of Charles River Laboratories

Wyc Grousbeck
Managing Partner and CEO of the Boston Celtics

Peter Hutt, LLB, LLM
Former FDA GC, SAB: Sirtris (NASDAQ: SIRT, now GSK), Alnara, OvaScience (NASDAQ: OVAS), Flex Pharma (NASDAQ: FLKS), BOD: Momenta (NASDAQ: MNTA)

Rod MacKinnon, PhD
Nobel Prize, Co-Founder Flex Pharma (NASDAQ: FLKS), Rockefeller University

John Maraganore, PhD
CEO Alnylam (NASDAQ: ALNY)

Brian McVeigh, CPA, CMA, CLP, MBA
GlaxoSmithKline, Vice President, WWBD Transactions and Investment Management

Richard Pops
Chairman and Chief Executive Officer Alkermes (NASDAQ: ALKS), BOD: Sirtris (NASDAQ: SIRT, now GSK)

Paul Schimmel, PhD
NAS, Scripps, Co-Founder Alnylam (NASDAQ: ALNY), Momenta (NASDAQ: MNTA) and Sirtris (NASDAQ: SIRT, now GSK)

John Sculley
Former President Pepsi, Former CEO, Apple, Investor: Flex Pharma (NASDAQ: FLKS)

Phil Sharp, PhD
Nobel Prize, Co-Founder Biogen and Alnylam (NASDAQ: ALNY), NAS, SAB: Sirtris (NASDAQ: SIRT, now GSK), Verastem (NASDAQ: VSTM)

David Sinclair, PhD
Harvard, Co-Founder/SAB Sirtris (NASDAQ: SIRT, now GSK), OvaScience (NASDAQ: OVAS)

Moncef Slaoui, PhD
GlaxoSmithKline, Chairman R&D

Henri Termeer (in memoriam)
Former Chairman, President and CEO Genzyme, BOD: Verastem (NASDAQ: VSTM)

Chris Walsh, PhD
Harvard, NAS, Genzyme, SAB: Sirtris (NASDAQ: SIRT, now GSK), Verastem (NASDAQ: VSTM), Flex Pharma (NASDAQ: FLKS)

SAB = Scientific Advisory Board, BOD = Board of Directors, NAS = National Academy of Sciences